Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 5/20 | 0.49 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12876205 | 0.81 | POLB (0.50) | LAP3ANPEPPOLBACP3TSHR | |
| SCHEMBL10714489 | 0.81 | LAP3 (0.51) | LAP3ANPEPPOLBACP3TSHR | |
| SCHEMBL9665263 | 0.77 | LAP3 (0.48) | LAP3ANPEPPOLBACP3TSHR | |
| SCHEMBL9667088 | 0.77 | LAP3 (0.48) | LAP3ANPEPPOLBACP3TSHR | |
| SCHEMBL8170213 | 0.75 | FDPS (0.66) | — | |
| SCHEMBL12876248 | 0.74 | PPARD (0.39) | LAP3POLBTSHRMMP8 | |
| SCHEMBL12876279 | 0.74 | ALDH1A1 (0.40) | LAP3POLBTSHR | |
| SCHEMBL12876302 | 0.73 | ALDH1A1 (0.43) | LAP3POLBTSHR | |
| SCHEMBL6772548 | 0.73 | ACP3 (0.51) | LAP3ANPEPPOLBACP3TSHR | |
| SCHEMBL9053712 | 0.72 | POLB (0.60) | LAP3ANPEPPOLBTSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034714-A1 | METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND | EKIMOTO HISAO | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034714-A1 | METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND | NR3C2, NR3C1, MC5R | LAP3 4122/4885ANPEP 4000/4885POLB 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.